• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention discloses methods for providing at least one oral care benefit by introducing a tablet into the oral cavity to generate a fluid and forcing at least a portion of fluid generated around the oral cavity, for example by wheezing. , rinsing, rinsing, etc. to provide an oral care benefit.
    公开号:BR112019010115A2
    申请号:R112019010115
    申请日:2017-10-13
    公开日:2019-08-20
    发明作者:R Geonnotti Anthony；Schackinger Boesen Dorthe；Ziegler Bruun Heidi；Wittorff Helle；L Golas Patricia
    申请人:Fertin Pharma As；Johnson & Johnson Consumer Inc；
    IPC主号:
    专利说明:

    Descriptive Report of the Invention Patent for METHOD TO PROVIDE BENEFITS OF ORAL TREATMENT. CROSS REFERENCE TO RELATED APPLICATION [001] This application is partly a continuation request, and claims the benefit of US application No. 15 / 356,175, filed on November 18, 2016 and also claims the benefit of international patent application No. PCT / DK2016 / 050377, filed on November 18, 2016.
    FIELD OF THE INVENTION [002] The present invention relates to a method for providing one or more benefits to the oral cavity. More specifically, the invention relates to methods of providing a tablet suitable for generating an amount of fluid to be rinsed in the oral cavity to provide one or more oral treatment benefits. BACKGROUND OF THE INVENTION [003] In a more perfect world, people would carefully clean their mouths after each meal as part of their routine oral hygiene practices. Unfortunately, several factors conspire to avoid widespread compliance with this basic requirement for a good mouthwash regimen.
    [004] Mouth cleaning can sometimes be difficult or inconvenient, depending on the nature of the cleaning and the situation in which cleaning needs to occur. Brushing, flossing, cleaning your tongue and gargling with the use of a variety of devices and compositions well suited to the privacy of a person's home are common oral care practices. However, devices and compositions used in mouth cleaning practices are less convenient to use outside the home, where sanitary facilities may be scarce, unavailable or unhygienic. For example, users of portable dental floss can clean their teeth wherever they are,
    Petition 870190053269, of 6/11/2019, p. 6/44
    2/31 but they are not discreet as well as not pleasant to use, so consumers do not use them properly.
    [005] As brushing, flossing, cleaning your tongue and gargling in public are not considered socially acceptable behaviors in many, if not all cultures, a variety of less invasive mouthwash products has been developed. These include gums and breath-freshening tablets. Although gums and lozenges have been formulated to achieve a variety of beneficial effects, they are not always socially acceptable. For example, gum is expressly prohibited in certain institutions, such as schools, as well as in certain countries. Gums and peppermint are used for extended periods of time, and require an amount of sucking or chewing action by the consumer, which can be distracting, tedious and undesirable.
    [006] Another product for portable mouth cleaning is a mouth spray. Like a mouthwash, a mouth spray can provide the consumer with a quick jet of strong breath-freshening action, which could be impressive in a long-lasting product like gums or lozenges. On the other hand, mouth sprayers are invasive. The sprinkling of a mouth spray typically generates a noise, which undesirably attracts the public's attention to the consumer. In addition, mouth sprayers are typically packaged in relatively expensive and complex metal tubes, which can clog in use and are not environmentally friendly. In addition, spraying the wrong direction not only wastes the product, but can result in irritated eyes, a sticky face and / or stained garments.
    [007] Therefore, it is desired to provide methods to provide at least one oral treatment benefit in easy to use forms. SUMMARY OF THE INVENTION
    Petition 870190053269, of 6/11/2019, p. 7/44
    3/31 [008] One aspect of the present invention provides methods for providing at least one oral treatment benefit by introducing a tablet into the oral cavity to generate a fluid and force at least a portion of the fluid generated around the oral cavity, for example, through mouthwash, rinse, wash, etc., to provide a mouth care benefit.
    DETAILED DESCRIPTION OF THE INVENTION [009] The present methods allow the use of a tablet to generate a fluid that can be moved throughout the oral cavity to provide a variety of oral treatment benefits, thereby leveraging the benefits associated with a tablet, including portability, ease of dosing, stability, including active stability, transport, processing benefits, and the like, while also providing efficacy and tactile / sensory benefits associated with a fluid shape, such as a mouthwash or mouthwash. Applicants have found that the methods of the present invention can be used to generate significant fluid in the mouth, compared to known uses of solid tablets / carriers, which can then be moved across the mouth to provide one or more benefits including, cleaning of the mouth, including debris removal, extermination of microorganisms, including antiplaque, anti-gingivitis, and reduction of unpleasant odor, dissolution of biofilm, prevention of bacterial fixation, modification of the structure of the oral microbial community, modification of the metabolic profile of microbes mouthwashes, antiviral activity, anti-inflammatory, pH balance, teeth whitening, stain prevention, anti-sensitivity agents, against cavities, enamel reinforcement, breath refreshment, oral hydration / relief of dry mouth, repair and prevention of erosion, a active application and retention, sensory improvement, alteration of sensation oral care, pain relief, wound healing, other benefits for
    Petition 870190053269, of 6/11/2019, p. 8/44
    4/31 teeth, mucosa, tongue and combinations of two or more of them.
    [0010] In certain embodiments, the methods of the present invention provide a unique combination of sensory properties in addition to the effectiveness in providing oral treatment benefits including, for example, a desirable chew resistance, mouth feel, irrigation effect and combinations of two or more of them. In certain embodiments, methods include depositing the tablet in the mouth and chewing which includes a mechanical bite / chew of the tablet. As discussed further below, in such embodiments, the tablets have a desired bite resistance or chew resistance. The mouthfeel provided in certain embodiments is preferably described as relatively mild, that is, with a reduced grainy or sandy sensation or a rapid transition out of any grainy or sandy sensation while chewing or dissolving the tablet in the mouth. Regarding the irrigation effect, it is preferable to have a salivation or irrigation effect to facilitate the benefits of mouth feeling and / or fluid generation.
    [0011] The methods of the present invention provide a surprising amount of generated fluid to be maintained and moved in the mouth over a period of time to enable one or more oral treatment benefits. In certain embodiments, the methods of the present invention use tablets to generate a mass of fluid, recorded as the quantity in grams at about 40 seconds (G40) measured using the Fluid Generation Test described below, which is about 4 grams or more, including about 4.1 grams or more, about 4.2 grams or more, about 4.3 grams or more, about 4.4 grams or more, about 4.5 grams or more, about in
    4.6 grams or more, about 4.7 grams or more, about 4.8 grams or more, about 4.9 grams or more and about 5 grams or
    Petition 870190053269, of 6/11/2019, p. 9/44
    5/31 more. In certain preferred embodiments, the methods use tablets that have a G40 of about 4.3 grams or more, including about 4.5 grams or more and about 4.8 grams or more. As shown in Example 2, for comparison, a variety of comparative tablets showed a G40 of less than 4 grams, including less than 3.9 and less than 3.5 grams.
    [0012] Any one of a variety of tablets can be used according to the present invention to generate fluid. In certain preferred embodiments, the tablets of the present invention are dissolvable, chewable tablets. As will be recognized by the person skilled in the art, chewable, soluble tablets include tablets that can be bitten and chewed by a user and tend to dissolve over time, as opposed to, for example, relatively stiff gums and / or solid shapes (eg example tablets and / or hard candies) which tend to be more difficult to bite (hard solid shapes) and / or contain portions that do not dissolve over time for normal use (gums). Consequently, the tablets of the present invention tend to have a hardness that makes it possible for a user to bite and chew the tablet, including, for example, a hardness of 300 Newtons (N) or less, as measured with the use of the Hardness Test. Tablet described here. In certain embodiments, the tablets of the present invention have a hardness of about 25 to about 250 N, including less than 200 N, about 25 to about 200 N, about 25 to about 160 N, about from 25 to about 100 N and from about 100 to about 200 N. In certain preferred embodiments, the tablets have a hardness of about 25 to about 160 N, about 25 to about 100 N, and about from 25 to about 50 N.
    [0013] The tablets of the present invention can be of any size / weight suitable for use in the generation of a fluid for
    Petition 870190053269, of 6/11/2019, p. 10/44
    6/31 use in methods. In certain embodiments, the tablets are larger than 1 gram, including about 1.1 grams or more, about 1.2 grams or more, about 1.3 grams or more, or about 1.5 grams or more. In certain preferred embodiments, the tablets are from about 1.1 grams to about 3 grams, including from about 1.1 grams to about 2.5 grams, from about 1.1 grams to about 2 grams, about 1.3 grams to about 2.5 grams, about 1.3 grams to about 2 grams, about 1.5 grams to about 2.5 grams and about 1.5 grams about 2 grams. In certain preferred embodiments, the tablets are about 1.3 to about 2 grams, including about 1.5 grams to about 2 grams.
    [0014] In certain embodiments, the tablets of the present invention can have any suitable thickness, including a thickness of about 5 to about 15 millimeters (mm), about 5 to about 12 mm, about 6 to about 12 mm, from about 8 to about 12 mm, from about 7 to about 8 mm. The tablets may also have a diameter, diagonal, or the length of the longest edge of any suitable size including from about 5 to about 20 mm, from about 8 to about 18 mm, from about 10 to about 18 mm mm, from about 12 to about 18 mm and from about 12 to about 16 mm.
    [0015] The tablets of the present invention can be prepared by any of a variety of tabletting methods known in the art. Conventional tablet production methods include direct compression (dry melting), dry granulation followed by compression, wet granulation followed by drying and compression, applying energy to a blend of materials to be formed into tablets, including applying heat, microwave, infrared, and other energies,
    Petition 870190053269, of 6/11/2019, p. 11/44
    7/31 combinations of two or more of the same and the like. Each of these methods is described in detail in the art and will be readily recognized by the person skilled in the art. In certain preferred embodiments, the tablets are produced by means of direct compression.
    [0016] The tablets of the present invention can comprise any of a variety of materials suitable for use therein. In certain embodiments, the tablets of the present invention comprise at least one carbohydrate. Examples of carbohydrates include, but are not limited to, sugars such as dextrose, dextrose monohydrate, lactose, glucose, fructose, maltodextrin, sucrose, corn syrup solids and mannose; carbohydrate alcohols, such as sugar alcohols including sorbitol, lactitol, xylitol, erythritol, mannitol, maltitol, isomalt and polyols; and combinations of two or more of the same. In certain preferred embodiments, the tablets comprise one or more sugar alcohols selected from the group consisting of xylitol, erythritol, maltitol and isomalt, including, for example, xylitol, maltitol and combinations thereof, or xylitol, erythritol, isomalt and combinations of the including combinations of xylitol, erythritol and isomalt. In certain preferred embodiments, the tablets comprise erythritol alone or in combination with one or more additional sugar alcohols. In certain preferred embodiments, the tablets comprise xylitol alone or in combination with one or more additional sugar alcohols. In other preferred embodiments, the tablets comprise one or more sugar alcohols selected from the group consisting of sorbitol, lactitol, xylitol, mannitol, maltitol, isomalt and combinations of two or more of the same.
    [0017] Carbohydrates for use in the present invention can be directly compressible (DC) or not directly compressible (non-DC). The terms DC and non-DC are readily understood
    Petition 870190053269, of 6/11/2019, p. 12/44
    8/31 by one skilled in the art. Suppliers of sugar alcohols provide clear guidance to the user as to their usability in relation to tablet compression. A non-DC particle in this connection is called a particle that is not expressly recommended by the supplier for compression. An example of a non-DC grade of erythritol is erythritol Zerose ™ 16952F available from Cargill while an example of a directly compressible grade (DC) of erythritol includes Zerose ™ DC 16966 also available from Cargill. In certain embodiments, the tablets comprise both DC and non-DC carbohydrates. In certain embodiments, the tablets comprise non-DC erythritol in combination with one or more DC sugar alcohols. In other embodiments, the tablets comprise DC carbohydrates and are substantially free of non-DC sugar alcohols. As used throughout the present invention, the term substantially free means a weight percent amount based on the weight of the tablet which is 10% or less, preferably 5% or less, preferably 1% or less, preferably 0.5% or less, preferably 0.1% or less of the substantially free material referenced. In certain embodiments, the term substantially free means that the tablet is free (has 0%) of the substantially free material referenced.
    [0018] In certain embodiments comprising non-DC erythritol, the amount of non-DC erythritol particles is relatively high. It is particularly high when considering that erythritol in a conventional sense is not considered attractive for compression, but the mouthfeel and salivation perceived by the user in such methods is improved when compared to low amounts or the same amounts of erythritol DC.
    [0019] In certain embodiments, the tablets of the present invention comprise a total amount of all carbohydrates
    Petition 870190053269, of 6/11/2019, p. 13/44
    9/31 in an amount of at least 40% by weight of the tablet, including about 40 to about 99%, about 60 to 99%, about 75 to about 95%, about 80 to about 90% by weight of the tablets. In certain preferred embodiments, the carbohydrates comprise one or more sugar alcohols and the tablet comprises a total amount of sugar alcohols of at least 40% by weight of the tablet, including from about 40 to about 99%, from about 60 about 99%, about 75 to about 95%, about 80 to about 90% by weight of the tablets. In certain embodiments, the tablets comprise at least 20% of each of two or more carbohydrates, including at least 20% of xylitol and at least 20% of one or more other sugar alcohols. In certain embodiments, the tablet comprises about 20-50% xylitol, including mixtures comprising about 20-50% xylitol and about 20-50% erythritol (DC or non-DC), including about 2050% xylitol, about 20-40% non-DC erythritol, and about 20-40% isomalt. In certain embodiments, the tablets comprise about 20-50% xylitol and at least 20% another sugar alcohol selected from the group consisting of sorbitol, lactitol, mannitol, maltitol, isomalt and combinations of two or more of the same .
    [0020] In certain embodiments, the tablets are sugar-free. As will be readily understood by the skilled person, such tablets may contain sugar alcohols but are nevertheless substantially free of sugars such as glucose, dextrose, sucrose, or oligomers / polymers of sugar molecules.
    [0021] The tablets of the present invention can comprise one or more active ingredients for use in providing an oral treatment benefit. In certain embodiments, the active ingredients
    Petition 870190053269, of 6/11/2019, p. 14/44
    10/31 includes, but is not limited to, any of a variety of assets to provide benefits such as mouth cleaning, including debris removal, antimicrobial, including antiplaque, anti-gingivitis and unpleasant odor reduction, biofilm dissolution, prevention of bacterial fixation, modification of the structure of the oral microbial community, modification of the metabolic profile of oral microbes, antiviral, anti-inflammatory activity, pH balance, teeth whitening, stain prevention, anti-sensitivity, against cavities, enamel reinforcement, refreshment breath, oral hydration / dry mouth relief, erosion repair and prevention, active application and retention, sensory improvement, altered mouth sensation, pain relief, wound healing and the like.
    [0022] In certain embodiments, the compositions of the present invention comprise essential oils. Essential oils are volatile aromatic oils that can be synthetic or can be derived from plants by distillation, expression or extraction, and which generally carry the aroma or flavor of the plant from which they are obtained. Useful essential oils can provide antiseptic activity. Some of these essential oils also act as flavoring agents. Useful essential oils include, but are not limited to, citra, thymol, menthol, methyl salicylate (oil of wintergreen), eucalyptol, carvacrol, camphor, anethole, carvone, eugenol, isoeugenol, limonene, osimen, n-decyl alcohol, citronium , a-salpineol, methyl acetate, citronellyl acetate, methyl eugenol, cineol, linalool, ethyl linalool, safrole vanillin, mint oil, mint oil, lemon oil, orange oil, sage oil, rosemary oil, cinnamon oil, pepper oil, bay oil, cedar leaf oil, gerianol, verbenone, anise oil, Indian bay oil, benzaldehyde, bergamot oil, bitter almond, chlorothymol, cinnamic aldehyde, citronella oil, oil cloves, coal tar, eucalyptus oil, guaiacol, tropolone derivatives such as hinokiti
    Petition 870190053269, of 6/11/2019, p. 15/44
    11/31 ol, lavender oil, mustard oil, phenol, phenyl salicylate, pine oil, pine needle oil, sassafras oil, lavender latifolia oil, storax, thyme oil, tolu balm, oil turpentine, clove oil, and combinations thereof.
    [0023] In certain preferred embodiments, the tablet of the present invention comprises one or more bioactive essential oils selected from the group consisting of menthol, thymol, eucalyptol and methyl salicylate. In certain preferred embodiments, the tablet comprises menthol and at least one other essential oil selected from thymol, eucalyptol and methyl salicylate. In certain preferred embodiments, the tablet comprises menthol and eucalyptol, menthol, eucalyptol and thymol, or menthol, eucalyptol, thymol and methyl salicylate. Thymol [(CH3) 2CHC6H3 (CH 3 ) OH, also known as isopropyl-mcresol], is only slightly soluble in water, but it is soluble in alcohol, and its presence is one of the reasons why alcohol was needed in mouthwashes with high alcohol content well established, commercially available. Methyl salicylate, [C6H4OHCOOCH3, also known as oil of wintergreen], additionally provides flavor to them along with their microbicidal function. Eucalyptol (CioHi 8 0, also known as cineol) is a terpene ether and provides a refreshing spicy taste. Eucalyptol can be used in place of thymol in certain formulations in the same amount, if desired. Menthol (CHsCeH ^ CsHyJOH), also known as hexahydrothymol) is also only slightly soluble in alcohol, and is quite volatile. Menthol, in addition to any antiseptic properties, provides a refreshing tingling sensation.
    [0024] Other suitable antimicrobial agents include halogenated diphenyl ethers, 2 ', 4,4' diphenyl trichloro-2-hydroxy-ether (Triclosan), 2,2'-dihydroxy-5,5'-dibromo-diphenyl ether, halic salicylanilides
    Petition 870190053269, of 6/11/2019, p. 16/44
    12/31 nothing, 4 ', 5-dibromo salicylanilide, 3,4', 5-trichloro salicylanilide, 3,4 ', 5tribromosalicylanilide, 2,3,3', 5-tetrachlorosalicilanilide, 3,3 ', 5-tetrachlorosalicilanilide, 3,5, dibromo-3'-trifluoromethyl salicylanilide, 5-n-octanoyl-3'trifluoromethyl salicylanilide, 3,5-dibromo-4'-trifluoromethyl salicylanilide,
    3.5- dibromo-3'-trifluoromethyl salicylanilide (Flurophene), benzoic esters, methyl-p-hydroxybenzoic ester, ethyl-p-hydroxybenzoic ester, propyl-p-hydroxybenzoic ester, butyl-p-hydroxybenzoic ester, halogenated carbanylides, 3,4 , 4 'trichlorocarbanilide, 3-trifluoromethyl4,4'- dichlorocarbanilide 3,3', 4-trichlorocarbanilide, phenolic compounds (including phenol and its counterparts, mono- and poly-alkyl and aromatic halophenols (for example, F, Cl, Br, I), resorcinol and catechol and their derivatives and bisphenolic compounds), 2 methyl phenol, 3 methyl phenol, 4 methyl phenol, 4 ethyl phenol, 2,4 dimethyl phenol, 2,5 dimethyl phenol, 3,4 dimethyl -phenol,
    2.6- dimethyl-phenol, 4-n-propyl-phenol, 4-n-butyl-phenol, 4-n-Amyl-phenol, 4-tert-Amyl-phenol, 4-n-hexyl-phenol, 4-n-heptyl phenol, 2-methoxy-4- (2-propenyl) phenol (Eugenol), Mono and polyalkyl and Aralkyl halophenols, Methyl-p-chlorophenol, ethyl-p-chlorophenol, n-propyl-p-chlorophenol, n-butyl-p -chlorophenol, nAmyl-p-chlorophenol, sec-Amyl-p-chlorophenol, n-hexyl-p-chlorophenol, cyclohexyl-p-chlorophenol, n-heptyl-p-chlorophenol, n-octyl-p-chlorophenol, O-chlorophenol , methyl-o-chlorophenol, ethyl-o-chlorophenol, n-propyl-o-chlorophenol, n-butyl-chloro-phenol, n-Amyl-o-chlorophenol tert-amyl-o-chlorophenol, n-hexyl-chloro-phenol, n- heptyl-o-chlorophenol, p-chlorophenol, o-benzyl-p-chlorophenol, obenzyl-m-methyl-p-chlorophenol o-benzyl-m, m-dimethyl-p-chlorophenol, o-phenylethyl-chlorophenol, o-phenylethyl -m-methyl-p-chlorophenol, 3-Methyl-p-chlorophenol, 3,5Di methyl-p-chlorophenol, 6-ethyl-3-methyl-p-chlorophenol, 6-n-propyl-3-methyl-p-chlorophenol, 6-iso-propyl-3-methyl-p-chlorophenol, 2-ethyl-3,5-dimethyl-p-chlorophenol, 6-sec butyl-3-methyl-p-chlorophenol, 2-iso-prop yl-3,5-dimethyl-p-chlorophenol, 6-Diethylmethyl-3-methyl-p-chlorophenol, 6-iso-propyl-2-ethyl-3-methyl-p-chlorophenol, 2-sec amyl-3,5-dimethyl-p -chlorophenol, 2-Diethylmethyl-3,5-dimethylp-chlorophenol, 6-sec octyl-3-methyl-p-chlorophenol, p-Bromophenol, Methyl-p-
    Petition 870190053269, of 6/11/2019, p. 17/44
    13/31
    Bromophenol, ethyl-p-Bromophenol, n-propyl-p-Bromophenol, n-butyl-pBromophenol, n-amyl-p-Bromophenol, sec-amyl-p-Bromophenol, n-hexyl-pBromophenol, cyclohexyl-p- Bromophenol, o-Bromophenol, tert-amyl-oBromophenol, n-hexyl-o-Bromophenol, n-propyl-m, m-Dimethyl-o-Bromophenol, 2-phenyl phenol, 4-chlorine, 2-methyl phenol, 4- chloro-3-methyl phenol, 4-chloro-3,5dimethyl phenol, 2,4-dichloro-3,5-dimethylphenol, 3,4,5,6-terabromo-2methylphenol, 5-methyl-2-pentylphenol, 4- isopropyl-3-methylphenol, 5-chloro-2hydroxydiphenylmethane, Resorcinol and its derivatives, Resorcinol, MethylResorcinol, ethyl-Resorcinol, n-propyl-Resorcinol, n-butyl-Resorcinol, namyl-Resorcinol, n-hexyl-Resorcinol, n -Resorcinol, n-octylResorcinol, n-Nonyl-Resorcinol, phenyl-Resorcinol, benzyl-Resorcinol, phenylethyl-Resorcinol, phenylpropyl-Resorcinol, p-chlorobenzyl-Resorcinol, 5chloro-2,4-dihydroxydiphenyl methane, 4'-chloro -2,4-dihydroxydiphenyl methane, 5-Bromo-2,4-dihydroxydiphenyl methane, 4'-Bromo-2,4-dihydroxydiphenyl methane, Bisphenolic compounds, Bisphenol A , 2,2'-methylene bis (4-chlorophenol), 2,2'-methylene bis (3,4,6-trichlorophenol) (hexachlorophene), 2,2'-methylene bis (4-chloro-6-bromophenol), bis ( 2-hydroxy-3,5-dichlorophenyl) sulfide, bis (2-hydroxy-5-chlorobenzyl) sulfide, menthoxy-1,2-propanediol, orthomethoxy cinnamic aldehyde, menthyl-3-hydroxybutanoate, combinations of two or more of the same and similar.
    [0025] Other antimicrobial agents include, but are not limited to: hexetidine; fatty acid compounds, such as capric acid, caprylic acid, capric acid, lauric acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid vitamin E, vitamin E acetate, apigenin and mixtures thereof; long-chain fatty alcohols, such as those described in US patent publication No. US 2011012 3462, to Mordas et al., incorporated herein by reference in their entirety (examples of which include, but are not limited to, 1-decen-3 -ol; cis-4-decen-1
    Petition 870190053269, of 6/11/2019, p. 18/44
    14/31 ol, trans-2-decen-1-ol, cis-2-nonen-1-ol, cis-4-decennial, trans-2-decennial, cis-7-decennial, cis-5-octen-1 -ol, trans-2-octen-1-ol, 1-octen-3-ol, cis-3nonen-1-ol, trans-2-nonen-1-ol, cis-6-nonen-1-ol, 9 -decen-1-ol, trans-2undecen-1-ol, trans-2-dodecen-1-ol, trans-2-octenal, trans-2-nonenal, 6-nonenal, cis-2-decenal, trans-2 -undecenal, trans-2-dodecenal, cis-3octen-1-ol, 3-octen-2-ol, 10-undecen-1-ol, trans-2-tridecen-1-ol, stereoisomers thereof and mixtures thereof ); cyclic sesouiterpene alcohols, such as farnesol; ester-N'-alkyl-L-arginine (e.g., lauroyl arginine ethyl ester) and salts such as those described in US patent 5,874,068 to Engelman al. et al, here incorporated by reference in its entirety; Compounds derived from amino acids as described in US Patent Publication No. 20160145203 to Gambogi, al. et al, incorporated herein by reference in its entirety; antimicrobial peptides, such as retrocycline (RC101), protegrin PG1 () or KSL-W; and surfactants, including cationic surfactants, such as cetylpyridinium chloride, chlorhexedine and mixtures thereof. In addition, antimicrobial extracts of certain botanical compounds or fruits may be included, including proanthocyanidins (PACs) found in cranberries such as flavan-3-ols (and polymers), procyanidins (and polymers), terpenes (and polymers), hydroxybenzyl acids , hydroxycinnamic acids, anthocyanidins (and polymers), flavonols (and polymers), and other cyanidins and peonidines. Oils, such as peppermint oil and sage oil, are also useful in the present invention.
    [0026] Suitable active ingredients include fluoride ion sources such as sodium fluoride, sodium monofluorophosphate, stannous fluoride, and amine fluorides (providing, for example, about 1 to 5,000 ppm fluoride ion, optionally about 200 to 1,150 ppm fluoride ion); non-fluoride tooth reinforcing agents such as calcium carbonate, alpha tricalcium phosphate, or calcium phosphoryl oligosaccharides, anti-calculating agents such as water-soluble pyrophosphate salts,
    Petition 870190053269, of 6/11/2019, p. 19/44
    15/31 preferably alkali metal pyrophosphates, polyacrylates and copolymers of anhydride or maleic acid and methyl vinyl ethers (eg Gantrez), as described, for example, in US Patent No. 4,627,977, to Gaffar et al .; as well as, for example, polyamino propane sulfonic acid (AMPS), zinc citrate trihydrate, polypeptides (such as polyaspartic and polyglutamic acids), and mixtures of two or more of the same; anti-calculating agents such as water-soluble pyrophosphate salts, preferably alkali metal pyrophosphates; chelating agents such as tartaric acid and its pharmaceutically acceptable salts, citric acid and alkali metal citrates and mixtures thereof; dental desensitizing agents that reduce tooth sensitivity including potassium salts like potassium nitrate and potassium chloride and strontium salts like strontium chloride and strontium acetate; teeth whitening agents and vitamins such as vitamin A; as well as pigments and dyes such as inorganic white pigments, inorganic colored pigments, pearling agents, fillers and the like, as well as talc, mica, magnesium carbonate, calcium carbonate, magnesium silicate, aluminum and magnesium silicate, silica, dioxide titanium, zinc oxide, red iron oxide, brown iron oxide, yellow iron oxide, black iron oxide, ferric ammonium ferrocyanide, manganese violet, oversea, nylon powder, polyethylene powder, methacrylate powder, polystyrene powder, Silk powder, crystalline cellulose, starch, titanium mica, titanium mica with iron oxide, bismuth oxychloride and mixtures of two or more of them.
    [0027] Enzymes are another type of active ingredient that can be used in the present compositions. Useful enzymes include those belonging to the category of proteases, lytic enzymes, plaque matrix inhibitors and suitable oxidases: Proteases include papain, pepsin, trypsin, ficin, bromelain; cell wall lytic enzymes
    Petition 870190053269, of 6/11/2019, p. 20/44
    16/31 include lysozyme; plaque matrix inhibitors include dextranases, mutanases; and oxidases include glucose oxidase, lactate oxidase, galactose oxidase and, uric acid oxidase, peroxidases including horseradish peroxidase, myeloperoxidase, lactoperoxidase, chloroperoxidase. Oxidases also have bleaching / cleaning activity, in addition to antimicrobial properties.
    [0028] Ingredients that are metabolized by oral bacteria to cause a beneficial effect on the oral cavity can also be included in these tablets, including arginine, arginine monohydrochloride, and inulin-like fructans, maltodextrin, fructooligosaccharides and galactooligosaccharides. In addition, these tablets can be used to release probiotic strains of bacteria, including certain species of lactobacilli and bifid bacteria, Saccharomyces spp, streptococci, enterococci and Escherichia co // co monthly.
    [0029] The tablet can also be used to release active pharmaceutical ingredients to treat diseases or symptoms of oral diseases that occur in the oral cavity or oropharynx, such as anesthetics, antibiotics, antifungals, antivirals, and anti-inflammatory compounds.
    [0030] In certain embodiments, tablets for use in the present invention can comprise any of a variety of salivating agents (also known as salivary or salivary stimulating agents). Suitable salivating agents include organic food acids such as citric, lactic, malic, succinic, ascorbic, adipic, fumaric, tartaric, parasympathomimetic drugs, such as choline esters such as pilocarpine hydrochloride, or cholinesterase inhibitors and combinations of two or more themselves. Additional suitable salivary stimulants are described, for example, in US patents 4,820,506 and 8,435,542 which are incorporated herein in their entirety. In certain preferential modalities
    Petition 870190053269, of 6/11/2019, p. 21/44
    17/31, salivating agents comprise citric acid, succinic acid or a combination thereof alone or in combination with other salivating agents. In certain preferred embodiments, the salivating agent comprises jambu oleoresin extract as described in US 8,435,542. The salivating agent can be present in any amount suitable for use in the present invention including, from about 0.001 to about 5% by weight of the tablet, including from about 0.01 to about 3%, from about 0, 01 to about 1%, from about 0.01 to about 0.5%, from about 0.01 to about 0.25% and from about 0.01 to about 0.1% by weight of the pill.
    [0031] Tablets for use in the present invention can comprise any of a variety of additional ingredients suitable for use in tablets including, for example, sweeteners, lubricants, fillers, adsorbents, disintegrators, glidants, super disintegrators, flavoring and flavoring agents, antioxidants, preservatives, texture enhancers, coloring agents and the like and mixtures of two or more of them.
    [0032] In certain embodiments, the tablets may comprise additional sweeteners including, but not limited to, synthetic or natural sugars; artificial sweeteners such as saccharin and its salts including sodium saccharin, aspartame, acesulfame and its salts including potassium acesulfame, thaumatin, glycyrrhizin, sucralose, dihydrocalcones, alitame, miraculin, monelin, stevioside, and combinations of two or more of the same. In certain preferred embodiments, the tablets comprise sucralose, acesulfame potassium or a combination thereof. The tablets can comprise any suitable total amounts of additional sweeteners including from 0.001 to about 8% by weight, including from about 0.02 to about 8%, from about 0.1 to about 3%, from about 0.1 to
    Petition 870190053269, of 6/11/2019, p. 22/44
    18/31 about 1%, and about 0.1 to about 0.5% by weight of the tablet.
    [0033] Tablets may also include lubricating materials in certain embodiments. Suitable lubricants include, but are not limited to, long-chain fatty acids and their salts, such as magnesium stearate and stearic acid, talc, glyceride waxes and mixtures thereof. Such materials can be present in any suitable amount including from about 0.01 to about 5%, including from about 0.1 to about 5%, from about 0.5 to about 3%, including from about from 0.5 to about 2% by weight of the tablet.
    [0034] Suitable fillers include, but are not limited to, water-insoluble plastic deformation materials (eg, microcrystalline cellulose or other cellulosic derivatives) and mixtures thereof. Suitable absorbents include, but are not limited to, water insoluble absorbents, such as dicalcium phosphate, tricalcium phosphate, solidified microcrystalline cellulose (for example, as distributed under the brand name PROSOLV (PenWest Pharmaceuticals, Patterson, NY, USA)), magnesium aluminum metasilicate (for example, as distributed under the brand name NEUSILIN (Fuji Chemical Industries (USA) Inc., Robbinsville, NJ)), clays, silicas, bentonite, zeolites, magnesium silicates, hydrotalcite, gum veegum and mixtures thereof. Suitable disintegrants include, but are not limited to, sodium starch glycolate, cross-linked polyvinyl pyrrolidone, cross-linked carboxymethyl cellulose, starches, microcrystalline cellulose and mixtures thereof.
    [0035] Examples of super disintegrators include, but are not limited to, croscarmellose sodium, sodium starch glycolate and cross-linked povidone (crospovidone). In one embodiment, the tablet contains up to about 5% by weight of such a super-disintegrator.
    [0036] Examples of flavorings and flavorings include, but are not limited to, essential oils including distillations, extractions by
    Petition 870190053269, of 6/11/2019, p. 23/44
    19/31 solvent or cold expressions of chopped flowers, leaves or peels, or of whole fruits reduced to pulp, containing mixtures of alcohols, esters, aldehydes and lactones; essences including or diluted solutions of essential oils, or mixtures of synthetic chemicals mixed together to resemble the natural flavor of the fruit (for example, strawberry, raspberry, and blackcurrant); artificial and natural flavors of fermented and distilled, for example cognac, whiskey, rum, gin, sherry, port and wine; tobacco, coffee, tea, cocoa and mint; fruit juices, including juice expelled from washed and rubbed fruits, such as lemon, orange, and lime; mint, peppermint, wintergreen, cinnamon, cocoa, vanilla, licorice, menthol, eucalyptus, anise seeds, oilseeds (for example, coconut peanuts, hazelnuts, chestnuts, walnuts, cola nuts), almonds, raisins; and parts of powder, flour or vegetable material, including ginger.
    [0037] Examples of antioxidants include, but are not limited to, tocopherols, ascorbic acid, sodium pyrosulfite, butylhydroxytoluene, butylated hydroxyanisole, edetic acid, edetate salts, and mixtures thereof.
    [0038] Examples of preservatives include, but are not limited to, citric acid, tartaric acid, lactic acid, malic acid, acetic acid, benzoic acid, and sorbic acid and mixtures thereof.
    [0039] Examples of texture enhancers include, but are not limited to, pectin, polyethylene oxide, and carrageenan, and mixtures thereof. In one embodiment, texture enhancers are used in grades from about 0.1% to about 10% per center by weight.
    [0040] In one embodiment, the tablets also contain one or more effervescent pairs. In one embodiment, the effervescent pair contains a member of the group consisting of sodium bicarbonate, potassium bicarbonate, calcium carbonate, magnesium carbonate and sodium carbonate and a selected member of the group consisting of
    Petition 870190053269, of 6/11/2019, p. 24/44
    20/31 in citric acid, malic acid, fumaric acid, tartaric acid, phosphoric acid and alginic acid. In one embodiment, the combined amount of effervescent pairs in the powder / tablet mixture is about 2 to about 20 percent by weight, for example from about 2 to about 10 percent, by weight of the mixed portion of powder / tablet. [0041] In some embodiments, tablets can be made by mixing their ingredients and heating them until they melt in a syrup then exposing the mixture to pressurized carbon dioxide gas (about 600 pounds per square inch, or psi) and allowing it to cool. The process causes tiny high pressure bubbles to be trapped inside the candy. When the tablet is placed in the mouth and comes in contact with the saliva, the tablet breaks and dissolves, releasing carbon dioxide from the bubbles, resulting in a crackling and wheezing sound and leaving a slight tingling sensation.
    [0042] As noted above, in preferred embodiments, the tablets of the present invention are not gums and are substantially free of gum bases, as conventionally used for the manufacture of gums, as opposed to chewable, dissolvable tablets. In preferred embodiments, the tablets of the present invention are not sufficiently heated to form hard candies or tablets as such terms and their manufacture are understood in the art and which product forms are intended to dissolve more slowly than dissolvable chewable tablets.
    [0043] The methods of the present invention comprise introducing into the oral cavity a tablet of the present invention. Any of a variety of known means can be used in the introduction step. For example, a pill can be placed by hand in a user’s mouth, the pill can be introduced through
    Petition 870190053269, of 6/11/2019, p. 25/44
    21/31 using an applicator, packaging, container, dosing apparatus, or other article or machine suitable for this purpose.
    [0044] The methods of the present invention further comprise generating a fluid in the oral cavity after the introduction of the tablet, preferably a fluid comprising ingredients of the tablet introduced into the oral cavity. As will be readily understood, in preferred embodiments, the step of generating a fluid includes stimulating the production of saliva in the oral cavity alone or in combination with other means to generate fluid. Preferably, the step of generating a fluid includes dissolving at least a portion of the tablet and stimulating the production of saliva in any order sequentially and / or simultaneously. In preferred embodiments, the fluid is generated in accordance with the present invention without introducing additional fluid, for example, water, solvent, or other drink or ingestable fluid into the oral cavity with the tablet. In preferred embodiments, the tablet is not mixed with water / fluid prior to or simultaneously with the introduction of the tablet into the oral cavity, nor is additional water / fluid added to the tablet in the oral cavity to generate the fluid according to the present invention.
    [0045] In certain embodiments, after the introduction of a tablet, the methods of the present invention comprise chewing said tablet to generate a fluid in the oral cavity, preferably chewing said tablet to dissolve, or during dissolution, at least one portion thereof and generate a fluid comprising ingredients of said tablet. The tablets can be chewed for any period of time sufficient to generate fluid according to modalities comprising a chewing step, including, for example, chewing for at least 5 seconds, including at least 10 seconds, at least 15 seconds, at least 20 seconds, or at least 30 seconds. In certain modali
    Petition 870190053269, of 6/11/2019, p. 26/44
    For preferred uses, the tablet is chewed for about 10 seconds or for at least 10 seconds.
    [0046] The present methods comprise the step of forcing at least a portion of the fluid generated around the oral cavity. As used herein, said step of forcing comprises applying any suitable amount of force within the oral cavity to move the fluid in any one or more directions, for example, from side to side, up, down, backwards, forwards, forwards, backwards, around, and / or through teeth, gums, cheek, and / or other surface of the oral cavity. In certain embodiments, the fluid is forced (a) from a lingual surface of the buccal cavity towards or over a buccal and / or labial surface of the buccal cavity, (b) from a buccal and / or labial surface of the oral cavity towards or on a lingual surface of the oral cavity, or both (a) and (b). In certain modalities, fluid is forced around the oral cavity using the muscle movements of the cheeks and / or the tongue. In certain modalities, the fluid is forced around the oral cavity with the lips closed. In certain preferred modalities, the step of forcing involves forcing at least a portion of the fluid generated around the mouth, with the lips closed, using the muscular movements of the cheeks and tongue. The fluid can be forced in any suitable manner according to the present invention, including, for example, by mouthwash, rinse, wash, spin, gargle, agitation, threshing, spilling, irrigation, actuation, spout, shower, flood, splash, splash, push, maneuver, mix, twist, flow, bathe, circulate, distribute, disperse, moisten, move, and the like, the fluid in any one or more directions, or otherwise use the fluid as a mouthwash , mouthwash, or other product for liquid oral treatment. The fluid can be forced / moved inside the
    Petition 870190053269, of 6/11/2019, p. 27/44
    23/31 oral cavity for any suitable period of time including at least 5 seconds, including at least 10 seconds, at least 15 seconds, at least 20 seconds, or at least 30 seconds. In certain preferred embodiments, the fluid is stirred for about 30 seconds or for at least 30 seconds.
    [0047] In certain modalities, the fluid generated in the present methods can be swallowed / ingested by a user or can be expelled / spat out after the movement step. In certain preferred embodiments, the methods comprise swallowing at least a portion of the fluid.
    [0048] Without the intention of being limiting, an example of a modality of the present method in use may include (a) introducing a pill into a user's oral cavity, in general said tablet being suitable to generate and / or fluid preferably having a G40 of at least 4 grams, (b) having the user chew the tablet to generate a fluid, preferably for an appropriate period of time to generate fluid, the fluid of which preferably contains materials / ingredients of the tablet that were introduced into it by chewing and / or dissolving at least a portion of the tablet; and (c) mouthwashing, or otherwise moving at least a portion of the fluid in the mouth prior to (d) swallowing. In another embodiment, a user can insert a tablet into the oral cavity and allow the tablet to dissolve to generate fluid, at least a portion of which is then moved into the oral cavity and then swallowed or expectorated.
    [0049] In certain preferred embodiments, the methods of the present invention comprise methods of cleaning the mouth. Such methods may include methods of removing debris from the oral cavity, including, for example, removing food particles or other debris on teeth or gums and / or providing breath freshening and
    Petition 870190053269, of 6/11/2019, p. 28/44
    24/31 extermination of germs associated with bad breath. Applicants have recognized that the present methods enable the generation of sufficient fluid from a tablet, as compared to prior art tablets, which can be moved throughout the mouth to effectively remove debris and / or release antimicrobial active ingredients from the tablet to the surfaces of the oral cavity to kill germs. In other preferred embodiments, the methods of the present invention comprise methods of killing germs associated with bad breath, plaque and / or gingivitis by introducing a tablet of the present invention that comprises at least one antimicrobial active ingredient.
    Examples
    Example 1 - Pills [0050] Pills E1-E4 and C1-C3 were made using the ingredients mentioned in Table 1. All ingredients were received in powder form. The ingredients were mixed in a blend of powders and tablets using a 6 ton SMI P2007-212b single station tablet press (E1, E2, C1, C2 tablets) or a Fette 3090i.
    Table 1
    Pill formula E1 E2 E3 E4 C1 C2 C3 Weight (grams) 1.5 g 1.5 g 1.6 g 1.2 g 1 g 1 g 1 g Ingredients (% by weight) Xylitol 20 20 38.94 38.94 20 20 20 Non-DC erythritol 27.5 27.5 Isomate 20.11 20.11 Maltitol 72.73 77.8 72.73 77.8 73.8 Calcium carbonate 7 7 Sucralose 0.15 0.15 0.16 0.16 0.15 0.15 0.15 Potassium acesulfame 0.05 0.05 0.055 0.055 0.05 0.05 0.05 Color 0.169 0.169
    Petition 870190053269, of 6/11/2019, p. 29/44
    25/31
    Pill formula E1 E2 E3 E4 C1 C2 C3 Magnesium stearate 2 2 1 1 2 2 2 Salivary agent 1 0.070.07 0.07 0.07 Flavor and aroma 2 55 5 5 Flavor 4
    1 Includes jambu oleoresin extract.
    2 Comprises menthol, eucalyptol, eugenol, mentoxy-1,2-propanediol, ortho-methoxy cinnamic aldehyde, menthol 3-hydroxy utanoate and other flavor ingredients.
    Example 2 - Fluid generation [0051] The fluid generation properties of the tablets were measured according to the Fluid Generation Test below to determine the amount in grams of the fluid generated after 40 seconds (G40) where the 40 seconds include chew for 10 seconds and rinse / move the fluid for 30 seconds. The G40 associated with the E1-E4 and C1-C3 tablets produced according to Example 1 was measured. Altoids® peppermint (C4) commercially available from Wrigley's was also measured having a list of ingredients including sugar, gum arabic, artificial flavors, gelatin, and color (Red 40), and an average weight measured to be about 0.72 grams.
    Fluid generation test [0052] Participants were given a tablet and instructed to chew the tablet for 10 seconds, then move the generated fluid around their mouth (rinse) for 30 seconds, then spit in the heavy mug previously. The final mass of the generated fluid spit in the mug after 40 seconds was determined: (final mass of the mug with saliva) - (empty mug mass) in grams. The overall mass mean of at least 8 (N) participants was reported as the G40 associated with the pills as listed in Table 2 below. Note: SEM = standard error of the mean.
    Petition 870190053269, of 6/11/2019, p. 30/44
    26/31
    Table 2 - Fluid generation
    C1 E1 C2 E2 E3 C4 E4 Average (G40) 3.88 4.72 3.94 4.37 5.09 3.24 4.33 ME V 0.22 0.25 0.22 0.28 0.26 0.23 0.31 N 12 13 13 10 12 9 9
    [0053] The Fluid Generation properties of tablets were also measured by means of paired comparison with other tablets by the same participant as shown in Tables 3 and 4 (each participant is compared with himself). The data reported in Table 3 are the difference in grams of the fluid generated by the first mentioned tablet minus the amount generated by the second mentioned tablet. The data reported in Table 4 are the percentage of fluid change generated by the first mentioned tablet compared to the second mentioned tablet. Table 3 - Paired comparison of fluid generation (mass)
    E1 vsC1 E2 vsC2 C1 vsC2 E1 vsE2 E3 vsE1 E3 vsC4 E4 vsC1 Average 0.89 0.59 0.08 0.33 0.33 1.76 0.48 ME V 0.19 0.23 0.13 0.21 0.11 0.19 0.23 N 12 10 11 10 12 9 9 95% Cl 0.37 0.46 0.26 0.42 0.21 0.38 0.45 P <0.05 Yes Yes Not Not Yes Yes Yes P <0.1 Yes Yes Not Yes Yes Yes Yes
    Table 4 - Paired comparison of fluid generation (percentage)
    E1 vsC1 E2 vsC2 C1 vsC2 E1 vsE2 E3 vsE1 E3 vsC4 E4 vsC1 Average 24% 19% 3% 9% 8% 57% 14% ME V 5% 8% 4% 6% 3% 8% 6% Score 12 10 11 10 12 9 9 95% Cl 9% 16% 7% 11% 5% 15% 12%
    Petition 870190053269, of 6/11/2019, p. 31/44
    27/31
    E1 vsC1 E2 vsC2 C1 vsC2 E1 vsE2 E3 vsE1 E3 vsC4 E4 vsC1 P <0.05 Yes Yes Not Not Yes Yes Yes P <0.1 Yes Yes Not Yes Yes Yes Yes
    Example 3 - Extermination of microorganisms [0054] The extermination properties of microorganisms associated with tablets were measured according to the following procedure:
    Materials • Previously reduced 9 ml 0.1% peptone tubes • Previously reduced 4.95 ml PO4 tubes • Sterile 18 mm glass test tubes with lids • Sterile 3 mm glass capsules • Sample tablets Sakura test tubes • Human saliva • Sterile stainless steel spatula • 1.9 ml autoclaved DIH2O tubes previously reduced • OOPS agar plates previously reduced
    Method for measuring the extermination of microorganisms • On the day before the test, pre-reduce all tubes and plates in an anaerobic chamber • Preparation of saliva inoculum o Group and homogenize saliva from a minimum of 6 donors.
    o Create a 50% saliva solution by adding 25 ml of 0.1% peptone previously reduced to 25 ml of saliva • Compress 1 sample tablet with a clean pestle and mortar (Clean with 70% IPA and clean with Kim handkerchief) and place in an 18 mm test tube with 6
    Petition 870190053269, of 6/11/2019, p. 32/44
    28/31 sterile 3 mm glass.
    • Add 4 ml of prepared preheated diluted saliva inoculum to the test tube with the crushed tablet (reaction tube) and start the timer o To test the water, like the negative control, place 1.9 ml in the test and add 4 ml of prepared preheated diluted saliva and vortex.
    o Vortex the reaction tube for a total of 35 or 45 seconds.
    o After the exposure time of 35 or 45 seconds, take 50 μΙ of the reaction mixture from the reaction tube and dispense in 4.95 ml of neutralizing broth and vortex for 5 seconds
    These will be called 10 2 dilutions.
    • Dilute and apply on OOPS III agar.
    • After 5 days at 35Ό of anaerobic incubation, the dark colonies (VSC producing organisms) were listed in OOPs III and compared to sterile water controls.
    • Percentage reductions compared to water treatment have been calculated.
    • The results are shown in Table 5.
    Table 5 - Extermination of microorganisms
    Name Water control C1 E1 C2 E2 E3 CFU / ml 1.29E + 07 1.66E + 06 4.37E + 05 1.34E + 07 1.22E + 07 2.17E + 06 Percentage reduction compared to water control at 87% 97% -4% 5% 83%
    Example 4 - Tablet hardness [0055] The tablet hardness was measured by a PharmaTest_ENB311E according to the instructions of the instrument (the Tablet hardness test). The results are shown in Table 6
    Petition 870190053269, of 6/11/2019, p. 33/44
    29/31 below. Note: SEM = standard error of the mean.
    Table 6
    Formula C1 C2 E1 E2 E3 C4 Thickness (mm) 7.50 7.78 10.91 11.11 7.48 6.11 Diameter / width (mm) 12.79 12.70 12.74 12.68 13.65 12.71 Medium hardness (in Newtons) 34.09 34.93 30.89 28.54 145.87 220.93 ME V 0.45 0.25 0.54 0.89 2.95 6.68 N 10 10 10 7 10 4
    Example 5 - Debris removal [0056] The ability / efficacy to remove debris according to the present methods was tested as described below.
    Debris removal test:
    Determination of the baseline amount of cracker residue left after chewing:
    [0057] Participants were instructed to chew a Saltine ™ cookie for 30 seconds and swallow. Immediately after swallowing, participants rinsed with 10 ml of water for 30 seconds and spit out the contents of their mouth in a disposable 50 ml sterile Millipore Steriflip® vacuum filtration system with a 100 Micron nylon mesh filter (number catalog number SCNY00100). Vacuum was applied for approx. 10 seconds until all the water is removed. Any excess liquid was pressed away from the edge of the filter. The filter with cracker residue was then weighed and the difference between the weight of the filter + cookie residue and the average weight of an unused Clean filter (N = 11) was calculated. This dough was used as the baseline amount of Cracker Biscuit left in a participant's mouth after eating a cracker biscuit.
    Determining the Amount of Cracker Residue Removed by Using the Tablet
    Petition 870190053269, of 6/11/2019, p. 34/44
    30/31 [0058] As before, participants were instructed to chew a Saltine ™ cookie for 30 seconds and swallow. Immediately after swallowing, participants were instructed to place an E3 tablet in their mouth, chew for 10 seconds, rinse the liquid for 30 seconds, then swallow. Immediately after swallowing, participants rinsed with 10 ml of water for 30 seconds and spit out the contents of their mouth in a disposable 50 ml Sterile Millipore Steriflip® vacuum filtration system with a 100 Micron nylon mesh filter (Number number SCNY00100). Vacuum was applied for approx. 10 seconds until all the water is removed. Any excess liquid was pressed away from the edge of the filter. The filter with cracker residue was then weighed and the difference between the weight of the filter + cookie residue and the average weight of an unused Clean filter (N = 11) was calculated. This dough was used as the amount of cracker left in a participant's mouth after chewing a cracker and using a tablet to clean the mouth and remove debris. The results are shown in Table 7.
    Table 7 - Removal of debris
    Participant Cracker residue baseline (grams) Cracker cookie residue after using E3 tablet (grams) Percentage reduction in waste (baseline - Tablet) / baseline * 100 1 0.8341 0.2915 65.05% 2 0.3396 0.234 31.10% 3 0.3295 0.1175 64.34% 4 0.3875 0.2998 22.63% 5 0.7535 0.4275 43.26% AVERAGE 45.28%
    Example 6 - Consumer tests [0059] Applicants assessed the consumer's experience in the
    Petition 870190053269, of 6/11/2019, p. 35/44
    31/31 use of the tablets as a solid form that can be chewed and generate fluid to be used, for example, as a mouthwash or mouthwash. The tablets of the present invention provide suitability as a chewable tablet and a desirable irrigation effect to produce sufficient fluid for rinsing.
    [0060] The classification of the consumer experience of the present methods in comparison with other methods has been tested. The results are shown in Table 8.
    Table 8
    % of participants issuing a report (N = 96) C3 E3 Very little liquid * 38% 19% Liked the chew and mouthwash experience with the product * 46% 61%
    * Significant at a 90% level
    权利要求:
    Claims (20)
    [1]
    1. Method for providing at least one oral treatment benefit characterized by the fact that it comprises introducing a tablet into the oral cavity, chewing said tablet to generate fluid in the oral cavity, and forcing at least a portion of the fluid generated around the oral cavity before swallowing or spitting said portion of fluid to provide an oral treatment benefit.
    [2]
    2. Method according to claim 1, characterized by the fact that said tablet is greater than 1 gram.
    [3]
    Method according to claim 2, characterized in that said tablet is about 1.2 grams or more.
    [4]
    4. Method according to claim 1, characterized by the fact that said tablet has a hardness less than 200 N.
    [5]
    5. Method according to claim 1, characterized by the fact that said tablet has a hardness of about 25 to about 160 N.
    [6]
    6. Method according to claim 1, characterized by the fact that said tablet has a G40 of about 4.3 grams or more.
    [7]
    Method according to claim 1, characterized in that said tablet comprises from about 40% to about 99% by weight of the tablet of one or more sugar alcohols selected from the group consisting of sorbitol, lactitol , xylitol, erythritol, mannitol, maltitol, isomalt and combinations of two or more of the same.
    [8]
    Method according to claim 7, characterized in that said tablet comprises at least 20% by weight of xylitol.
    [9]
    9. Method according to claim 7, characterized in that said tablet comprises xylitol, erythritol and isomal-
    Petition 870190053269, of 6/11/2019, p. 37/44
    2/3 te.
    [10]
    10. Method according to claim 9, characterized in that said erythritol comprises erythritol that is not directly compressible.
    [11]
    11. Method according to claim 7, characterized by the fact that said tablet is essentially free of non-directly compressible erythritol.
    [12]
    12. Method according to claim 1, characterized in that said tablet comprises a salivary agent.
    [13]
    13. Method according to claim 1, characterized by the fact that said tablet comprises at least one essential oil selected from the group consisting of menthol, thymol, eucalyptol, methyl salicylate, and combinations of two or more of the same.
    [14]
    14. Method according to claim 1, characterized in that said step of forcing comprises forcing the fluid around the oral cavity for at least 30 seconds.
    [15]
    15. Method of cleaning the oral cavity, characterized by the fact that it comprises:
    The. introduce into the oral cavity a tablet comprising a salivary agent and from about 60 to about 99%, by weight, of sugar alcohols selected from the group consisting of sorbitol, lactitol, xylitol, erythritol, mannitol, maltitol, isomalt and combinations of two or more of the same, said tablet having a weight of about 1.3 to about 2 grams;
    B. chewing said tablet to generate fluid in the oral cavity;
    ç. forcing said fluid generated around the oral cavity; and
    d. swallowing at least a portion of said generated fluid.
    [16]
    16. Method according to claim 15, characterized by the fact that said tablet has a hardness of about 25
    Petition 870190053269, of 6/11/2019, p. 38/44
    3/3 at about 160 N.
    [17]
    17. Method according to claim 16, characterized in that said tablet additionally comprises one or more antimicrobial essential oils.
    [18]
    18. Method, according to claim 17, characterized by the fact that said method comprises exterminating germs associated with bad breath, plaque, gingivitis or combinations of two or more of them.
    [19]
    19. Method according to claim 18, characterized in that said one or more antimicrobial essential oils comprise menthol, thymol, eucalyptol, methyl salicylate, or a combination of two or more of the same.
    [20]
    20. Method according to claim 19, characterized in that said step of forcing comprises forcing said fluid for at least 30 seconds before swallowing.
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112019010115A2|2019-08-20|method of providing oral hygiene benefits
    US20180140521A1|2018-05-24|Method of Providing Oral Care Benefits
    RU2388457C2|2010-05-10|Breath refresher for disinfecting oral cavity and containing magnolia bark extract and surface active substance
    RU2396941C2|2010-08-20|Fillers with magnolia bark extract for oral cavity care
    RU2338549C2|2008-11-20|Product with extract of magnolia bark, freshening breath and disinfecting oral cavity
    US6656493B2|2003-12-02|Edible film formulations containing maltodextrin
    RU2398593C2|2010-09-10|Fast-release chewing composition with magnolia bark extract
    RU2396970C2|2010-08-20|Breath refreshing confectionery composition
    RU2241436C2|2004-12-10|Aromatic mixture for masking unpleasant taste of zinc compounds
    JP2013501782A|2013-01-17|Oral care composition
    RU2392924C2|2010-06-27|Composition against fetid breath
    RU2398594C2|2010-09-10|Confectionery compositions containing magnolia bark extract
    MX2007002561A|2007-04-24|Oral care composition comprising essential oils.
    CN105828885B|2018-10-12|Oral care composition and method
    CN102046158B|2013-08-14|Oral compositions containing enhanced antibacterial combinations of antioxidants and extracts of magnolia
    US20070098650A1|2007-05-03|Dental formulation
    CN102573769B|2013-12-04|Dentifrice composition
    EP2520278B1|2018-08-01|Means for removing tobacco tars and composition containing same
    CN102548526B|2015-06-10|Dentifrice composition
    KR20130060084A|2013-06-07|Composition for preventing or treating peridontal disease
    US20200188245A1|2020-06-18|Method of Providing an Oral Care Benefit using a Poorly-soluble Calcium Compound and Fluoride
    RU2557981C2|2015-07-27|Compositions and methods for oral cavity care
    CN102781439B|2015-11-25|Oral care composition and method
    JP2012527455A|2012-11-08|Oral composition
    KR20200012181A|2020-02-05|Toothpaste composition comprising herbal extract mixture as effective component
    同族专利:
    公开号 | 公开日
    AU2017360584B2|2020-12-17|
    EP3541359A1|2019-09-25|
    AU2017360378A1|2019-06-06|
    KR20190086512A|2019-07-22|
    DK3541359T3|2021-02-22|
    EP3541360A1|2019-09-25|
    RU2736072C1|2020-11-11|
    JP6840849B2|2021-03-10|
    AU2021200826A1|2021-03-04|
    RU2019118433A|2020-12-18|
    MX2019005928A|2019-11-12|
    RU2019118433A3|2020-12-18|
    JP2019535732A|2019-12-12|
    CN109952092A|2019-06-28|
    CA3044382A1|2018-05-24|
    BR112019008138A2|2019-07-02|
    CA3040830A1|2018-05-24|
    CA3040830C|2021-06-15|
    MA46822A|2019-09-25|
    CN110087634A|2019-08-02|
    MX2019005828A|2019-07-08|
    EP3541359B1|2021-01-27|
    ES2860802T3|2021-10-05|
    PL3541359T3|2021-05-31|
    AU2021200826B2|2022-02-17|
    JP2019535729A|2019-12-12|
    WO2018091050A1|2018-05-24|
    WO2018093501A1|2018-05-24|
    AU2017360584A1|2019-05-02|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4627977A|1985-09-13|1986-12-09|Colgate-Palmolive Company|Anticalculus oral composition|
    US4820506A|1987-05-01|1989-04-11|Research Foundation, State University Of New York|Salivary stimulant|
    TW469135B|1995-10-03|2001-12-21|Chugai Pharmaceutical Co Ltd|Chewable tablet|
    EP1380308B1|1996-07-12|2008-07-09|Daiichi Pharmaceutical Co., Ltd.|Quickly disintegrable compression-molded materials and process for producing the same|
    GB9716432D0|1997-08-05|1997-10-08|Cerestar Holding Bv|Tableting of erythritol|
    US5874068A|1997-12-08|1999-02-23|Warner-Lambert Company|Stabilized antiplaque and antigingivitis oral compositions containing N.sup.α -alkyl-L-arginine alkyl ester salts|
    WO2000025598A1|1998-11-03|2000-05-11|Dandy A/S|Sucrose fatty acid esters for use as increased release of active ingredients|
    CN1494419A|2001-03-06|2004-05-05|协和发酵工业株式会社|Preparations quickly disintegrating in oral cavity|
    US8435542B2|2005-03-03|2013-05-07|Takasago International Corp. |Synergistic salivation agents|
    JP2006335686A|2005-06-02|2006-12-14|Hamari Chemicals Ltd|Method for producing erythritol-sorbitol mixed granule for direct tableting|
    CN1709229A|2005-06-10|2005-12-21|北京阜康仁生物制药科技有限公司|Memantine hydrochloride orally disintegrating tablet and its preparing method|
    CN100446759C|2006-10-16|2008-12-31|北京科信必成医药科技发展有限公司|Gastrodine tablets disintegrating in oral cavity and process for producing same|
    JP5766899B2|2007-04-11|2015-08-19|ニプロ株式会社|Oral disintegrant and method for producing the same|
    WO2009007768A1|2007-07-06|2009-01-15|Gumlink A/S|Compressed tablet comprising polyol|
    ES2388494T3|2007-07-27|2012-10-15|Cargill, Incorporated|Micronization of Polyols|
    SI2334202T1|2008-09-04|2012-04-30|Cargill Inc|Tabletting of ervthritol|
    US9591852B2|2009-11-23|2017-03-14|Mcneil-Ppc, Inc.|Biofilm disruptive compositions|
    US8658139B1|2010-02-27|2014-02-25|Squigle, Inc.|Prevention and treatment of oral diseases|
    WO2013125350A1|2012-02-23|2013-08-29|フロイント産業株式会社|Direct-compression excipient for orally disintegrating tablet and method for producing same, and orally disintegrating tablet|
    US10357054B2|2013-10-16|2019-07-23|R.J. Reynolds Tobacco Company|Smokeless tobacco pastille|
    US10463620B2|2014-10-16|2019-11-05|Cargill, Incorporated|Process for preparing a directly compressible erythritol and uses thereof|
    RU2020125263A3|2014-11-11|2021-02-19|
    CN104546807B|2015-01-21|2020-09-01|齐鲁制药有限公司|Olanzapine oral instant film agent|US10543205B2|2016-11-18|2020-01-28|Fertin Pharma A/S|Oral delivery vehicle containing nicotine|
    US10632076B2|2016-11-18|2020-04-28|Fertin Pharma A/S|Tablet comprising separate binder and erythritol|
    US11058633B2|2018-05-17|2021-07-13|Fertin Pharma A/S|Disintegrating oral tablet suitable for active pharmaceutical ingredients|
    US11096894B2|2018-05-17|2021-08-24|Fertin Pharma A/S|Oral tablet for induced saliva generation|
    US11096896B2|2018-05-17|2021-08-24|Fertin Pharma A/S|Tablet dosage form for buccal absorption of active ingredients|
    US20190350858A1|2018-05-17|2019-11-21|Fertin Pharma A/S|Oral tablet for delivery of active ingredients to the gastrointestinal tract|
    US11135157B2|2018-05-17|2021-10-05|Fertin Pharma A/S|Oral tablet for delivery of active ingredients to the throat|
    US11052047B2|2018-05-17|2021-07-06|Fertin Pharma A/S|Oral tablet suitable for fast release of active pharmaceutical ingredients|
    AU2019268497B2|2018-05-17|2022-01-06|Fertin Pharma A/S|A tableted chewing gum suitable for active pharmaceutical ingredients|
    US11058641B2|2018-05-17|2021-07-13|Fertin Pharma A/S|Oral tablet for taste masking of active ingredients|
    US11096895B2|2018-05-17|2021-08-24|Fertin Pharma A/S|Oral tablet suitable for active pharmaceutical ingredients|
    US11090263B2|2018-05-22|2021-08-17|Fertin Pharma A/S|Tableted chewing gum suitable for active pharmaceutical ingredients|
    KR102345862B1|2021-03-18|2022-01-03|김현진|Solid oral cleaning composition comprising popping component|
    法律状态:
    2021-03-09| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
    2021-04-27| B07G| Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]|
    2021-08-31| B06W| Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]|
    2021-10-05| B350| Update of information on the portal [chapter 15.35 patent gazette]|
    优先权:
    申请号 | 申请日 | 专利标题
    US15/356,175|US10543205B2|2016-11-18|2016-11-18|Oral delivery vehicle containing nicotine|
    PCT/DK2016/050377|WO2018091048A1|2016-11-18|2016-11-18|Oral delivery vehicle|
    PCT/US2017/056554|WO2018093501A1|2016-11-18|2017-10-13|Method of providing oral care benefits|
    [返回顶部]